Compare ESPR & ATNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | ATNI |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 406.5M |
| IPO Year | 2013 | 1994 |
| Metric | ESPR | ATNI |
|---|---|---|
| Price | $3.14 | $27.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 17.1M | 49.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.03% |
| EPS Growth | ★ 60.71 | 34.29 |
| EPS | ★ N/A | N/A |
| Revenue | $403,135,000.00 | ★ $727,975,000.00 |
| Revenue This Year | N/A | $3.12 |
| Revenue Next Year | $12.81 | $1.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.76 | $13.76 |
| 52 Week High | $4.18 | $30.45 |
| Indicator | ESPR | ATNI |
|---|---|---|
| Relative Strength Index (RSI) | 70.96 | 47.57 |
| Support Level | $3.11 | $25.13 |
| Resistance Level | $3.18 | $27.66 |
| Average True Range (ATR) | 0.02 | 1.21 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 43.75 | 67.73 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.